BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 11301685)

  • 1. Selective COX-2 inhibitors.
    Pasero C; McCaffery M
    Am J Nurs; 2001 Apr; 101(4):55-6. PubMed ID: 11301685
    [No Abstract]   [Full Text] [Related]  

  • 2. [Side effects cause enormous costs. Expensive arthritis therapy].
    MMW Fortschr Med; 2001 Nov; 143(46):60. PubMed ID: 11759607
    [No Abstract]   [Full Text] [Related]  

  • 3. [Specific cyclo-oxygenase inhibitors. 2. Gastric toxicity?].
    Blondon H
    Presse Med; 2000 Mar; 29(9):482-3. PubMed ID: 10745938
    [No Abstract]   [Full Text] [Related]  

  • 4. [Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart].
    MMW Fortschr Med; 2003 Mar; 145(11):60. PubMed ID: 12688204
    [No Abstract]   [Full Text] [Related]  

  • 5. [Cox-2 inhibitors in the focus. Rofecoxib as effective as the "classics"].
    MMW Fortschr Med; 2001 Nov; 143(46):50-1. PubMed ID: 11759601
    [No Abstract]   [Full Text] [Related]  

  • 6. What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex).
    Wooltorton E
    CMAJ; 2002 Jun; 166(13):1692-3. PubMed ID: 12126328
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinical pharmacology of the selective COX-2 inhibitors].
    Burian M; Geisslinger G
    Orthopade; 2003 Dec; 32(12):1078-87. PubMed ID: 14655004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective COX-2 inhibition.
    Silas S; Clegg DO
    Bull Rheum Dis; 1999; 48(2):1-4. PubMed ID: 12024416
    [No Abstract]   [Full Text] [Related]  

  • 9. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COX-2 inhibitors. Magic bullets or merely mortal?
    Harv Health Lett; 2000 Feb; 25(4):4. PubMed ID: 10637015
    [No Abstract]   [Full Text] [Related]  

  • 11. Rofecoxib vs celecoxib vs acetaminophen for treatment of osteoarthritis.
    Henderson P
    JAMA; 2002 Apr; 287(14):1799; author reply 1799-800. PubMed ID: 11939848
    [No Abstract]   [Full Text] [Related]  

  • 12. Rofecoxib vs celecoxib vs acetaminophen for treatment of osteoarthritis.
    Bierma-Zeinstra SM; Bohnen AM; Berger MY; Thomas S
    JAMA; 2002 Apr; 287(14):1799; author reply 1799-800. PubMed ID: 11939847
    [No Abstract]   [Full Text] [Related]  

  • 13. [New treatment of pain and fever in rheumatoid arthritis and arthrosis. The first cyclooxygenase-2 inhibitors show promising results].
    Oliw E; Wollheim FA
    Lakartidningen; 2000 Jun; 97(24):2942-4. PubMed ID: 10900877
    [No Abstract]   [Full Text] [Related]  

  • 14. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of rheumatoid arthritis and osteoarthritis with COX-2-selective inhibitors: a managed care perspective.
    Hochberg MC
    Am J Manag Care; 2002 Nov; 8(17 Suppl):S502-17. PubMed ID: 12458820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.
    Zhao SZ; Wentworth C; Burke TA; Makuch RW
    Pharmacoepidemiol Drug Saf; 2004 May; 13(5):277-87. PubMed ID: 15133778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Gastrointestinal complications caused by NSAIDs. Over 60% of arthrosis patients are endangered].
    MMW Fortschr Med; 2003 Mar; 145(10):60. PubMed ID: 12688036
    [No Abstract]   [Full Text] [Related]  

  • 18. Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis.
    Ann Intern Med; 2003 May; 138(10):I39. PubMed ID: 12755582
    [No Abstract]   [Full Text] [Related]  

  • 19. COX-2 inhibition and thrombotic tendency: a need for surveillance.
    Cleland LG; James MJ; Stamp LK; Penglis PS
    Med J Aust; 2001 Aug; 175(4):214-7. PubMed ID: 11587283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular and renal effects of COX-2-specific inhibitors: recent insights and evolving clinical implications.
    Epstein M
    Am J Ther; 2001; 8(2):81-3. PubMed ID: 11304661
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.